Mirum Pharmaceuticals, Inc. , a leading rare disease company, today provided its preliminary and unaudited estimates for full-year 2025 net product sales, year-end cash balance, corporate updates and ...
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 monthsNotable ...
Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today reports preliminary* fourth quarter and full-year 2025 net product revenues and cash, cash equivalents, ...
The data illustrate that several patients remained on zenocutuzumab well beyond progression, including multiple patients who continued treatment for more than one- or two-years post-progression.
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...
A small set of common blood biomarkers predicts which older adults will develop specific combinations of chronic diseases—and ...
Noida: Yamuna Expressway Industrial Development Authority (YEIDA) will develop 13 laboratories, including a gamma radiation facility, at the planned Medical Device Park (MDP) in Sector 28 of Yamuna ...
Clinicians discuss the rapidly evolving therapies, technology, and surgical approaches for early-stage NSCLC and take a fresh look at the future of care. Teamwork: A Multidisciplinary Approach to ...
The use of radiation in medicine is continuously evolving, due to clinical and technological developments. New imaging and therapy modalities require accurate dosimetry and comprehensive quality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback